Johnson & Johnson (JNJ) is scheduled to report its fiscal second-quarter results before the market opens on July 15. JNJ stock is a “Dividend King” because it has increased its dividend for 64 consecutive years. Johnson & Johnson is one of the world’s largest and oldest healthcare companies. Currently, JNJ pays a regular quarterly dividend of $1.34 per share, reflecting an above-industry-average yield of 2.5%. JNJ last increased its dividend on April 14, 2026, when the board approved a 3.1% dividend hike to $1.34 per share.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
The Street expects JNJ to post adjusted earnings per share (EPS) of $2.86, up from $2.77 reported in the prior-year period. Similarly, sales are expected to rise 5.4% year-over-year to $25.02 billion. Notably, JNJ has beaten earnings expectations in seven of the past eight quarters, while matching estimates once.
In Q1 FY26, JNJ beat earnings expectations, driven by solid performance in its Innovative Medicine segment, where drugs like Darzalex and Carvykti posted robust sales growth. The company also lifted its full-year 2026 outlook, raising the midpoint of its sales guidance to $100.8 billion and increasing adjusted EPS guidance to $11.55.
Options Traders Expect a 3.8% Price Swing
According to TipRanks’ Options Traders Tool, options traders are pricing in a 3.79% move in either direction for JNJ stock in reaction to Q2 results. This implied move is higher than the stock’s average post-earnings move (in absolute terms) of 1.74% over the past four quarters.
Here’s What Analysts Are Saying
Recently, Bank of America Securities analyst Jason Gerberry raised his price target on JNJ from $254 to $263, implying 2.3% upside potential. He expects large pharmaceutical companies with durable drug portfolios to continue performing well. However, he kept his Hold rating on JNJ because he believes companies facing patent expirations on key drugs are likely to struggle.
Citi analyst Joanne Wuensch also lifted her price target from $285 to a new Street-high of $298, implying nearly 16% upside, while keeping her Buy rating. She prefers high-quality medtech companies, including Johnson & Johnson, which could outperform as investors look for safer and more reliable stocks amid the current uncertain market.
Is JNJ Stock a Good Buy?
Overall, analysts remain cautiously optimistic about JNJ’s long-term outlook. On TipRanks, JNJ has a Moderate Buy consensus rating based on 11 Buys and five Hold ratings. The average Johnson & Johnson price target of $268.07 implies 4.3% upside potential from current levels. Year-to-date, JNJ shares have gained 24.8%.
